Last published market research from plusdetudes.com related to Cardiovascular diseases. http://www.plusdetudes.com/ci0228/-market-research.html 2007-08-21T12:45:16Z Increasingly the large pharmaceutical companies are pumping money and ambition into the DNA/RNA therapy market. Whether its through forming collaboration/licensing agreements, or acquiring smaller companies they can see the financial opportunities. I http://www.plusdetudes.com/p056721/Top-Companies-and-Products-in-the-RNADNA-Therapy-Products-Market-Forecasts-The-challenge-of-turning-technology-into-therapy.html http://www.plusdetudes.com/p056721/Top-Companies-and-Products-in-the-RNADNA-Therapy-Products-Market-Forecasts-The-challenge-of-turning-technology-into-therapy.html This Database Table is a one-page table of hard-to-find numerical information. The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specific data points. The Database Table is NOT a report or http://www.plusdetudes.com/p054707/US-Insulin-Delivery-Market-2005-2010.html http://www.plusdetudes.com/p054707/US-Insulin-Delivery-Market-2005-2010.html This Database Table is a one-page table of hard-to-find numerical information. The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specific data points. The Database Table is NOT a report or http://www.plusdetudes.com/p054689/Cardiac-Catheter-Lab-Procedures-2002-2010.html http://www.plusdetudes.com/p054689/Cardiac-Catheter-Lab-Procedures-2002-2010.html Datamonitor's Amylin Pharmaceuticals Inc - SWOT Analysis Company Profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides s http://www.plusdetudes.com/p054599/Amylin-Pharmaceuticals-Inc-SWOT-Analysis.html http://www.plusdetudes.com/p054599/Amylin-Pharmaceuticals-Inc-SWOT-Analysis.html Datamonitor's United Therapeutics Corp. - SWOT Analysis Company Profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides su http://www.plusdetudes.com/p054490/United-Therapeutics-Corp-SWOT-Analysis.html http://www.plusdetudes.com/p054490/United-Therapeutics-Corp-SWOT-Analysis.html Datamonitor's Sciele Pharma, Inc. - SWOT Analysis Company Profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary http://www.plusdetudes.com/p054332/Sciele-Pharma-Inc-SWOT-Analysis.html http://www.plusdetudes.com/p054332/Sciele-Pharma-Inc-SWOT-Analysis.html Datamonitor's CV Therapeutics, Inc - SWOT Analysis Company Profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary http://www.plusdetudes.com/p054662/CV-Therapeutics-Inc-SWOT-Analysis.html http://www.plusdetudes.com/p054662/CV-Therapeutics-Inc-SWOT-Analysis.html Datamonitor's Eli Lilly and Company - SWOT Analysis Company Profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summar http://www.plusdetudes.com/p054321/Eli-Lilly-and-Company-SWOT-Analysis.html http://www.plusdetudes.com/p054321/Eli-Lilly-and-Company-SWOT-Analysis.html “By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight, researcher has found”. For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatm http://www.plusdetudes.com/p056722/Anti-Obesity-Treatments-2007-2012--A-blockbuster-target-market.html http://www.plusdetudes.com/p056722/Anti-Obesity-Treatments-2007-2012--A-blockbuster-target-market.html IntroductionDatamonitor expects the antihypertensives market to reach almost $40 billion, across the seven major markets, by 2016. The growth will be driven by the uptake of Novartis's Tekturna, as well as increased use of ARBs, and their com http://www.plusdetudes.com/p054278/PipelineCommercial-Insight-Antihypertensives-New-class-opportunity-offset-by-key-patent-expiries.html http://www.plusdetudes.com/p054278/PipelineCommercial-Insight-Antihypertensives-New-class-opportunity-offset-by-key-patent-expiries.html